CASE REPORT
Published on 16 Sep 2022
Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
![Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report](https://www.frontiersin.org/files/myhome article library/912490/912490_Thumb_400.jpg)
doi 10.3389/fonc.2022.912490
- 1,945 views
- 9 citations